Trial Profile

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dacarbazine (Primary) ; Unesbulin (Primary)
Indications Leiomyosarcoma; Liver metastases
Focus Registrational; Therapeutic Use
Acronyms SUNRISELMS
Sponsors PTC Therapeutics

Most Recent Events

19 Mar 2025 Status changed from active, no longer recruiting to discontinued.
25 Jul 2024 This trial has been completed in France, according to European Clinical Trials Database record.
22 Feb 2024 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com